Skip to main content
//empty //empty
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you manage your health, your finances and your family life as Canada reopens.
Visit the hub

A medical worker shows an antibody rapid serological test for COVID-19, on May 6, 2020 at the Tor Vergata Covid hospital in Rome, during the country's lockdown aimed at curbing the spread of the COVID-19 infection, caused by the novel coronavirus.

TIZIANA FABI/AFP/Getty Images

Health Canada says it has authorized the first COVID-19 serological test for use in the country to detect antibodies specific to the virus.

DiaSorin, an Italian multinational biotechnology company, had developed the LIAISON test that was also recently approved by the U.S. Food and Drug Administration.

In a statement Tuesday, Health Canada says it will be used in Canadian laboratories to detect COVID-19 antibodies and help contribute to a better understanding of whether people who have been infected are immune to the virus.

Story continues below advertisement

Health Canada says further research will also help understand the relationship between positive antibody tests and protection against reinfection.

The Canadian agency says at least one million Canadian blood samples will be collected and tested over the next two years to track the virus in the general population and in specific groups at greater risk of having been infected, including health-care workers and seniors.

It says the testing will help inform public health decisions to protect the health of Canadians.

“Health Canada will continue to focus on the health and safety of Canadians while expediting supply of safe and effective health products related to COVID-19,” the statement says.

Follow related topics

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies